Alumis Inc. Common Stock
ALMSAlumis Inc. (ALMS) is a biotechnology company focused on developing innovative therapies and solutions primarily within the healthcare and life sciences sectors. The company emphasizes advancing scientific research and technology to address unmet needs in medical treatments, often concentrating on areas such as antibody engineering and advanced therapeutics.
Company News
Cormorant Asset Management increased its stake in Alumis by 313,645 shares ($7.84 million) in Q1 2026, bringing its position to 4.37% of assets. Alumis shares have surged 400% over the past year, driven by strong Phase 3 psoriasis trial data for its lead drug envudeucitinib. The company has $569.5 million in cash and plans to submit an NDA in Q4 ...
Over 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include...
Alumis announced positive Phase 3 results for envudeucitinib, a TYK2 inhibitor for moderate-to-severe plaque psoriasis. The drug achieved PASI 90 responses in 68.0% and 62.1% of patients by Week 24, with PASI 100 complete clearance in 41.0% and 39.5%. Quality-of-life improvements and itch relief emerged early, with a favorable safety profile. The...
Alumis Inc., a clinical-stage biopharmaceutical company, announced the pricing of an upsized underwritten public offering of 17.65 million shares at $17.00 per share, generating approximately $300 million in gross proceeds. The offering is expected to close on January 9, 2026, with underwriters granted a 30-day option to purchase an additional 2....
Alumis shares surged 94.53% following positive Phase 3 trial results for envudeucitinib, an oral TYK2 inhibitor for psoriasis that met primary and secondary endpoints. The company announced plans to raise $175 million in capital to support commercialization of the drug and its pipeline. The broader market rose modestly with the S&P 500 gaining 0....
